Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Apellis Pharmaceuticals Inc (APLS)
Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,793,215
  • Shares Outstanding, K 120,582
  • Annual Sales, $ 75,420 K
  • Annual Income, $ -652,170 K
  • 60-Month Beta 0.90
  • Price/Sales 19.43
  • Price/Cash Flow N/A
  • Price/Book 37.75
Trade APLS with:

Options Overview Details

View History
  • Implied Volatility 58.34% ( +2.07%)
  • Historical Volatility 47.13%
  • IV Percentile 24%
  • IV Rank 13.62%
  • IV High 182.18% on 07/28/23
  • IV Low 38.81% on 06/21/23
  • Put/Call Vol Ratio 0.73
  • Today's Volume 1,510
  • Volume Avg (30-Day) 1,298
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 40,629
  • Open Int (30-Day) 42,815

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.53
  • Number of Estimates 10
  • High Estimate -0.28
  • Low Estimate -0.88
  • Prior Year -1.56
  • Growth Rate Est. (year over year) +66.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.98 +5.99%
on 02/29/24
71.90 -10.11%
on 02/26/24
+2.07 (+3.31%)
since 02/02/24
3-Month
46.44 +39.17%
on 12/14/23
73.80 -12.43%
on 01/09/24
+0.76 (+1.19%)
since 12/04/23
52-Week
19.83 +225.92%
on 08/07/23
94.75 -31.79%
on 06/14/23
-0.35 (-0.54%)
since 03/03/23

Most Recent Stories

More News
Stocks Set to Open Lower as Investors Weigh Powell’s Remarks, Earnings and Fed Speak in Focus

March S&P 500 E-Mini futures (ESH24) are down -0.24%, and March Nasdaq 100 E-Mini futures (NQH24) are down -0.12% this morning as U.S. Treasury yields climbed on relatively hawkish comments from Federal...

ESH24 : 5,123.25 (-0.29%)
NQH24 : 18,173.25 (-0.49%)
META : 498.19 (-0.82%)
EW : 87.02 (+2.11%)
AMZN : 177.58 (-0.36%)
CHTR : 279.06 (-4.81%)
MCD : 290.94 (+0.07%)
CAT : 338.65 (+0.58%)
LLY : 792.28 (+1.30%)
F : 12.74 (+2.33%)
AMGN : 279.39 (-0.34%)
DIS : 113.69 (+1.55%)
Moderna, Rivian rise; Apellis, Adobe fall, Thursday, 12/14/2023

Stocks that traded heavily or had substantial price changes on Thursday: Moderna, Rivian rise; Apellis, Adobe fall

HES : 145.61 (-1.74%)
MRNA : 96.00 (+0.99%)
APLS : 64.63 (+1.16%)
GKOS : 88.56 (-0.29%)
T : 16.80 (-1.06%)
ADBE : 567.94 (-0.52%)
MKKGY : 34.3100 (+0.12%)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023

/PRNewswire/ -- Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders: The Law Offices of Vincent Wong announce that a class action...

APLS : 64.63 (+1.16%)
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...

APLS : 64.63 (+1.16%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS). Such...

APLS : 64.63 (+1.16%)
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action...

APLS : 64.63 (+1.16%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action...

APLS : 64.63 (+1.16%)
Why Shares of Apellis Pharmaceuticals Were Down Wednesday

A short-seller report sent the stock tumbling.

APLS : 64.63 (+1.16%)
APLS NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)...

APLS : 64.63 (+1.16%)
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS

/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 2, 2023 to file lead plaintiff applications...

APLS : 64.63 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 70.68
2nd Resistance Point 68.34
1st Resistance Point 66.49
Last Price 64.63
1st Support Level 62.29
2nd Support Level 59.95
3rd Support Level 58.09

See More

52-Week High 94.75
Fibonacci 61.8% 66.13
Last Price 64.63
Fibonacci 50% 57.29
Fibonacci 38.2% 48.45
52-Week Low 19.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar